N. Demircan, T. Akın Telli, Tuğba Başoğlu, R. Arıkan, Alper Yaşar, A. Celebı, Özkan Alan, S. Isik, Özlem Ercelep, F. Dane, P. Yumuk
{"title":"Clinicopathological Features, Treatment Outcomes, and Prognostic Factors in Adrenocortical Carcinoma: A Single-Center Experience","authors":"N. Demircan, T. Akın Telli, Tuğba Başoğlu, R. Arıkan, Alper Yaşar, A. Celebı, Özkan Alan, S. Isik, Özlem Ercelep, F. Dane, P. Yumuk","doi":"10.37047/jos.2021-84514","DOIUrl":null,"url":null,"abstract":"gland is adrenocortical carcinoma (ACC). ACC is a highly rare malignancy, with an incidence of 0.7-2 per million population.1 Although a diagnosis can be made at any age, ACC more frequently affects women, and its incidence peaks in the fourth to fifth decades of life.2 ACCs are generally sporadic; however, they are occasionally observed as a component of hereditary syndromes like Li-Fraumeni or Beckwith-Wiedemann syndrome.3 Approximately 60% of patients present with symptoms owing to adrenal hormone secretion, where cortisol excess (Cushing syndrome) is the leading manifestation followed by secretion of sex hormones (primarily androgen).1,4 Non-functional ACCs cause symptoms owing to tumor burden, particularly abdominal pain and weight loss. Most ACC cases are diagnosed at an advanced stage, and 5-year survival remains below 50%.5","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37047/jos.2021-84514","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
gland is adrenocortical carcinoma (ACC). ACC is a highly rare malignancy, with an incidence of 0.7-2 per million population.1 Although a diagnosis can be made at any age, ACC more frequently affects women, and its incidence peaks in the fourth to fifth decades of life.2 ACCs are generally sporadic; however, they are occasionally observed as a component of hereditary syndromes like Li-Fraumeni or Beckwith-Wiedemann syndrome.3 Approximately 60% of patients present with symptoms owing to adrenal hormone secretion, where cortisol excess (Cushing syndrome) is the leading manifestation followed by secretion of sex hormones (primarily androgen).1,4 Non-functional ACCs cause symptoms owing to tumor burden, particularly abdominal pain and weight loss. Most ACC cases are diagnosed at an advanced stage, and 5-year survival remains below 50%.5